+ All Categories
Home > Documents > 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Date post: 17-Jan-2016
Category:
Upload: lucas-andrews
View: 213 times
Download: 0 times
Share this document with a friend
Popular Tags:
23
30 patient drug sensitivity data Figure S1
Transcript
Page 1: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

30 patient drug sensitivity data

Figure S1

Page 2: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2AMyeloid regulator enrichment in AML

Page 3: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2BMyeloid regulator enrichment in cALL

Page 4: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2CMyeloid regulator enrichment in CLL

Page 5: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S2DMyeloid regulator enrichment in MDS

Page 6: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3AMalacards AML

Page 7: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3BMalacards cALL

Page 8: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3CMalacards CLL

Page 9: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S3DMalacards MDS

Page 10: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4ACGC AML

Page 11: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4BCGC cALL

Page 12: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4CCGC CLL

Page 13: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S4DCGC MDS

Page 14: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S5

Page 15: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S6

Page 16: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S7

Page 17: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S8Apoptosis AML

Page 18: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Signal transduction

Immune response

Mitochondrial function

Celluar cytoskeletonHeme biosynthesis

Figure S9

Page 19: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

BCL-2

BAX

Known anti-apoptotic factors

A key mitochondrial pro-apoptotic protein

Ohtsuka et al (2004)

PYCARD Apoptosis SER in AML

A key mediator in apoptosis and inflammation

Youle et al (2008)

FIGURE S10

Page 20: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S11

Page 21: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S12

Page 22: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S13

Page 23: 30 patient drug sensitivity data Figure S1. Figure S2A Myeloid regulator enrichment in AML.

Figure S14


Recommended